SkinBioTherapeutics 'on track' for commercialisation of AxisBiotix in Q4

Life science company SkinBioTherapeutics said on Thursday that commercialisation of its AxisBiotix-Ps product was "on track" for the fourth quarter of 2021.

SkinBioTherapeutics stated that further analysis of data from a recent evaluation of AxisBiotix also revealed "encouraging potential" to treat eczema, acne, and rosacea after the cream found significant reductions in itchiness, redness, irritability and flakiness.

The AIM-listed group said its commercial strategy ahead of the roll-out was to initially target the US and UK markets, with the EU set to become a focal point shortly thereafter.

Excluding shipping and duty costs, AxisBiotix will be marketed on a subscription basis and priced per sachet in the US at $2.00, at £1.50 in the UK and €1.80 in Europe.

Elsewhere, SkinBio said its partner Croda and its active ingredients arm, Sederma, were continuing to "progress the development" of the firm's SkinBiotix technology.

SkinBio aims to produce 20,000 cubic metres by September, marking the final step towards commercialisation of the product.

"We are very pleased with the progress the company has been able to make over the first half of this year, both with AxisBiotix-Ps and SkinBiotix," said chief executive Stuart Ashman.

As of 1030 BST, SkinBio shares were down 1.52% at 66.48p.